Third data and safety monitoring board meeting for EffiKIR trial recommends continuation as planned

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board (“DSMB”) completed its third assessment of the EffiKIR study and recommended continuation of the trial, as planned.

Enrolment in the EffiKIR study was completed in July 2014 and data on the primary endpoint, Leukemia-Free Survival, are expected end of 2015.

As specified in the study protocol, the DMSB meets every six months to examine the safety data accumulated during progress of the trial. A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. DSMBs are customarily established for large randomized multisite studies.